|
|
News Breaks | | | | November 8, 2012 | | 11:52 EDT |  | PSTI | Pluristem lack of disclosure on patient death in legal gray area, Bloomberg says
Pluristem Therapeutics' (PSTI) stock soared and at least two top executives profited in spite of the fact that a patient reportedly died months after using its experimental stem cell treatment, according to Bloomberg. The company has yet to make an announcement of the girl’s death, which may put it in a legal gray area in regards to U.S. securities laws, the report noted. Reference Link | |
|
News For PSTI From The Last 14 Days Check below for free stories on PSTI the last two weeks. |
|
|
| May 13, 2013 | | 06:23 EDT |  | PSTI | Pluristem Therapeutics' PLX cells may be effective in treating preeclampsia
 Subscribe for More Information | | | May 8, 2013 | | 07:12 EDT | | PSTI | Pluristem Therapeutics announces Phase 1 trial to study PLX-PAD cells
Pluristem announced a new Phase I trial to check safety and evaluate effectiveness of its PLX-PAD cells in chronic tendonitis often leading to rotator cuff disorders, common in tennis players and golfers, where there are roughly 200,000 rotator cuff surgeries done each year in the US alone. Major insurers put the overall cost of rotator cuff operations at $6,700 each, with a lucrative $1,700 in doctor fees, draining our health care system of over $1.3B. | | | May 7, 2013 | | 05:47 EDT | | PSTI | Pluristem Therapeutics develops PLX-RAD cells for use in Hematology
Subscribe for More Information | |
|
|
|
|
|
|
